----------------------------------------------
Substance Exposed Newborn Committee (941) 373-7070
The Florida Center for Childhood Development (941) 371-8820
Healthy Families (941) 371-8820
Florida FASD Clinic (941) 371-8820
Sarasota Memorial Hospital Neonatal Intensive Care Unit (941) 917-6530
Child'Space (941) 362-0944
First Step of Sarasota Mothers and Infants (941) 366-5333
Sarasota Department of Children and Families (877) 595-0384
Family Partnership Center (941) 756-3007
Sarasota County Prescription Drug Take Back
Camp Mariposa
National Acupuncture Detoxification Association
----------------------------------------------
American Academy of Pediatrics Recommendations:
1. Screening for maternal substance abuse should involve multiple forms, including maternal history, maternal urine testing, and testing of newborn urine and newborn meconium specimens.
2. Drug withdrawal should be considered as a diagnosis in infants in whom compatible signs develop.
3. Drug withdrawal should be scored using an appropriate scoring tool.
4. Pharmacologic therapy of withdrawal-associated seizures is indicated.
5. Vomiting, diarrhea, or both, associated with dehydration and poor weight gain, in the absence of other diagnoses, are relative indications for treatment, even in the absence of high total withdrawal scores.
6. Drug selection should match the type of agent causing withdrawal.
7. Physicians should be aware that the severity of withdrawal signs, including seizures, has not been proven to be associated with differences in long-term outcome after intrauterine drug exposure.
8. The use of naloxone in the delivery room is contraindicated in infants whose mothers are known to be opioid-dependent. However, in the absence of a specific history of opioid abuse, naloxone treatment remains a reasonable option in the delivery room management of a depressed infant whose mother recently received a narcotic.